pharmaphorum4 天
Zytiga is powerhouse for J&J - but for how long?
The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...
pharmaphorum2 天
J&J gets restricted label for PARP drug Akeega in EU
The EMA’s human medicines committee has recommended approval for Akeega, a fixed-dose combination of J&J’s PARP drug Zejula (niraparib) and androgen inhibitor Zytiga (abiraterone acetate), in ...
Cure Today4 天
Erleada Combo Shows Comparable Quality of Life Outcomes in Prostate Cancer
A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.
Citi maintains ORIC stock Buy rating, $13 target ahead of PFE data
Citi reaffirmed its Buy rating and $13.00 price target for ORIC Pharmaceuticals (NASDAQ:ORIC), whose stock currently trades at $10.15. The company has shown strong momentum with a 25.77% year-to-date ...
花旗维持ORIC制药买入评级，目标价13美元，静待辉瑞数据公布
周二，花旗重申了对ORIC制药（NASDAQ:ORIC）的买入评级和13.00美元的目标价。该公司股票目前交易价格为10.15美元。尽管近期市场波动，该公司年初至今仍录得25.77%的强劲回报。该机构预计，ORIC的股价将在2月13日显著上涨，届时辉瑞（PFE）的ASCO ...